	US 12,378,320 B2
	Methods for treating pancreatitis
Dannielle D. Engle, San Diego, CA (US); and David A. Tuveson, Cold Spring Harbor, NY (US)
Assigned to Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (US)
Appl. No. 17/274,783
Filed by Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (US)
PCT Filed Sep. 9, 2019, PCT No. PCT/US2019/050262 § 371(c)(1), (2) Date Mar. 9, 2021, PCT Pub. No. WO2020/055768, PCT Pub. Date Mar. 19, 2020.
Claims priority of provisional application 62/729,354, filed on Sep. 10, 2018.
Prior Publication US 2022/0049011 A1, Feb. 17, 2022
Int. Cl. C07K 16/30 (2006.01); A61P 1/18 (2006.01); C07K 16/28 (2006.01)

CPC C07K 16/2896 (2013.01) [A61P 1/18 (2018.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/626 (2013.01); C07K 2317/76 (2013.01)]

38 Claims

1. A method for treating, ameliorating, or managing pancreatitis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antibody or functional fragment thereof that binds to Sialyl-Lewis^a(anti-sLe^a), wherein said anti-sLe^aantibody or functional fragment comprises:

(i) a variable heavy chain (VH) domain comprising three VH complementarity defining regions (CDRs) present in the amino acid sequence of SEQ ID NO: 2; and a variable light chain (VL) domain comprising three VL CDRs present in the amino acid sequence of SEQ ID NO: 4;

(ii) a VH domain comprising three VH CDRs present in the amino acid sequence of SEQ ID NO: 6; and a VL domain comprising three VL CDRs present in the amino acid sequence of SEQ ID NO: 8;

(iii) a V5 domain comprising three V2 CDRs present in the amino acid sequence of SEQ ID NO: 10; and a VL domain comprising three VL CDRs present in the amino acid sequence of SEQ ID NO: 12;

(iv) a VH domain comprising three VH CDRs present in the amino acid sequence of SEQ ID NO: 14; and a VL domain comprising three VL CDRs present in the amino acid sequence of SEQ ID NO: 16: or

(v) a VH domain comprising three VH CDRs present in the amino acid sequence of an antibody produced by a hybridoma deposited under American Type Culture Collection (ATCC) Accession No. HB-8059; and a VL domain comprising three VL CDRs present in the amino acid sequence of an antibody produced by a hybridoma deposited under American Type Culture Collection (ATCC) Accession No. HB-8059.